Cargando…

A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice

Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a key role in the initiation and regulation of humoral and cellular immunity. DC vaccines loaded with different tumor-associated antigens (TAAs) have been widely used to study their therapeutic effects on cancer. A number o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Jiayi, Zeng, Wuyi, Jia, Jiangtao, Shi, Yi, Wang, Danni, Dong, Jun, Fang, Zixuan, He, Jiashan, Yang, Xinyu, Zhang, Rong, He, Menghua, Huang, Maoping, Fu, Bishi, Zhong, Bei, Liu, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325010/ https://www.ncbi.nlm.nih.gov/pubmed/35891256 http://dx.doi.org/10.3390/vaccines10071092

Ejemplares similares

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy
por: Zeng, Wuyi, et al.
Publicado: (2022)

MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
por: Lakshminarayanan, Vani, et al.
Publicado: (2016)

Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody
por: Fang, Jun, et al.
Publicado: (2023)

MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization
por: Son, Hye-Youn, et al.
Publicado: (2022)

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells
por: Li, Yumei, et al.
Publicado: (2018)

MUC1 promotes lung metastases of liver cancer by impairing anti-tumor immunity
por: Yin, Yanze, et al.
Publicado: (2023)

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer
por: Wang, Yue, et al.
Publicado: (2023)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Wang, Miao, et al.
Publicado: (2021)

Local Effects of Regulatory T Cells in MUC1 Transgenic Mice Potentiate Growth of MUC1 Expressing Tumor Cells In Vivo
por: Sugiura, Daisuke, et al.
Publicado: (2012)

MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer
por: Cheng, Jian-Ping, et al.
Publicado: (2011)

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
por: Hillman, Gilda G., et al.
Publicado: (2017)

The research status and prospects of MUC1 in immunology
por: Long, Linna, et al.
Publicado: (2023)

Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
por: Curry, Jennifer M., et al.
Publicado: (2019)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway
por: Zhang, Yinghui, et al.
Publicado: (2020)

Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting
por: Li, Zhaoyi, et al.
Publicado: (2019)

The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF
por: Behrens, Michelle E., et al.
Publicado: (2010)

TG4010: A therapeutic vaccine against MUC1 expressing tumors
por: Limacher, Jean-Marc, et al.
Publicado: (2012)

MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
por: Beatson, Richard, et al.
Publicado: (2016)

Effect of MUC1 Mucin, an Anti‐adhesion Molecule, on Tumor Cell Growth
por: Makiguchi, Yusuke, et al.
Publicado: (1996)

Characterization of tumor-associated MUC1 and its glycans expressed in mucoepidermoid carcinoma
por: Isaka, Eisaku, et al.
Publicado: (2021)

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2020)

ecDNA within tumors: a new mechanism that drives tumor heterogeneity and drug resistance
por: Zeng, Xixi, et al.
Publicado: (2020)

MUC1-C REPRESSES THE RASSF1A TUMOR SUPPRESSOR IN HUMAN CARCINOMA CELLS
por: Rajabi, Hasan, et al.
Publicado: (2019)

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
por: Remy-Ziller, Christelle, et al.
Publicado: (2017)

Expression of MUC1 and MUC4 in Gallbladder Adenocarcinoma
por: Kim, Su-Mi, et al.
Publicado: (2012)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
por: Vesterinen, Tiina, et al.
Publicado: (2019)

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
por: Betge, Johannes, et al.
Publicado: (2016)

Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
por: Sam, Johannes, et al.
Publicado: (2021)

The role of exosomal PD-L1 in tumor immunotherapy
por: Wang, Jing, et al.
Publicado: (2021)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Alterations in Mucin Expression in Ovarian Mucinous Tumors: Immunohistochemical Analysis of MUC2, MUC5AC, MUC6, and CD10 Expression
por: Hirabayashi, Kenichi, et al.
Publicado: (2008)

Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells
por: Rajabi, Hasan, et al.
Publicado: (2019)

MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice
por: Yang, Ming, et al.
Publicado: (2012)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1—Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?
por: Wang, Lishi, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mnkck94h7gvpgtd8vaahk7h1jt